J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on August 1, 2008

Papers In Press, published online ahead of print April 17, 2008
J. Lipid Res., doi:10.1194/jlr.M800102-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M800102-JLR200v1
49/8/1746    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Cabre, A.
Right arrow Articles by Masana, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cabre, A.
Right arrow Articles by Masana, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Submitted on February 27, 2008
Revised on April 10, 2008
Accepted on April 16, 2008

Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes

Anna Cabre, Iolanda Lazaro, Josefa Girona, Josep M. Manzanares, Francesc Marimon, Nuria Plana, Mercedes Heras, and Lluis Masana

Department of Internal Medicine, Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, Sant Joan University Hospital, Reus, Tarragona 43201

Corresponding Author: luis.masana{at}urv.cat

The aim of this study was to evaluate the impact of adipocyte fatty acid binding protein (FABP4) on the lipid profile in type 2 diabetic subjects. Plasma levels of FABP4, adiponectin, and an extensive lipid profile were analyzed in 169 type 2 diabetic subjects and 105 controls. Type 2 diabetic subjects were categorized according the presence of atherogenic dyslipidemia. Univariate statistical analyses, partial correlation tests, and binary logistic regression models were applied. In type 2 diabetic subjects, FABP4 was positively correlated with plasma triglycerides (p=0.007), apo C3 (p=0.009), and all the components of triglyceride-rich lipoproteins (TRL), including VLDL-triglycerides (p=0.002), VLDL-cholesterol (p=0.001) and VLDL-apo B (p=0.001). FABP4 was inversely correlated with apo A1 (p=0.038), HDL-cholesterol (p=0.002) and HDL-apo A1 (p=0.010) in type 2 diabetic subjects. These correlations are not significantly affected by age, gender, BMI, adiponectin, insulin, or any pharmacological treatment. The associations are even stronger when the FABP4/adiponectin ratio is considered. None of these associations were observed in controls. High FABP4 and low adiponectin levels are independent predictors of atherogenic dyslipidemia. In conclusion, FABP4 plasma concentrations hold strong potential for development as a clinical biomarker for atherogenic dyslipidemia, independent of obesity and insulin resistance, in type 2 diabetic subjects.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.